DE3687736D1 - Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. - Google Patents

Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.

Info

Publication number
DE3687736D1
DE3687736D1 DE8686307735T DE3687736T DE3687736D1 DE 3687736 D1 DE3687736 D1 DE 3687736D1 DE 8686307735 T DE8686307735 T DE 8686307735T DE 3687736 T DE3687736 T DE 3687736T DE 3687736 D1 DE3687736 D1 DE 3687736D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
breast cancer
human breast
hybridome
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686307735T
Other languages
English (en)
Other versions
DE3687736T2 (de
Inventor
David Barratt Ring
Arthur Edward Frankel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of DE3687736D1 publication Critical patent/DE3687736D1/de
Publication of DE3687736T2 publication Critical patent/DE3687736T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
DE8686307735T 1985-10-07 1986-10-07 Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. Expired - Fee Related DE3687736T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78507685A 1985-10-07 1985-10-07
US06/786,948 US4938948A (en) 1985-10-07 1985-10-11 Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies

Publications (2)

Publication Number Publication Date
DE3687736D1 true DE3687736D1 (de) 1993-03-25
DE3687736T2 DE3687736T2 (de) 1993-05-27

Family

ID=27120360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686307735T Expired - Fee Related DE3687736T2 (de) 1985-10-07 1986-10-07 Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.

Country Status (13)

Country Link
US (1) US4938948A (de)
EP (1) EP0220858B1 (de)
JP (3) JP2968474B2 (de)
AT (1) ATE85652T1 (de)
AU (1) AU6356986A (de)
CA (1) CA1338706C (de)
DE (1) DE3687736T2 (de)
DK (1) DK478886A (de)
ES (1) ES2053440T3 (de)
FI (1) FI864037A (de)
IL (1) IL80231A (de)
NO (1) NO863974L (de)
NZ (1) NZ217829A (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
AU613590B2 (en) * 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US7255851B2 (en) * 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
DE10141937A1 (de) * 2001-08-28 2003-03-27 Alfred Schmidt Markierung der Aromatase
DE60233744D1 (de) 2001-09-20 2009-10-29 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
EP1501855A4 (de) * 2002-03-21 2006-02-22 Sagres Discovery Inc Neue zusammensetzungen und verfahren bei krebs
US6916474B2 (en) 2002-07-15 2005-07-12 Board Of Regents, The University Of Texas System Antibodies with increased affinities for anthrax antigens
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
ATE546158T1 (de) * 2004-01-27 2012-03-15 Univ Southern California Therapeutisches krebsmittel mit polymergebundenem antikörper
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP5085326B2 (ja) 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
EP1872136B9 (de) 2005-04-04 2023-02-08 Biogen MA Inc. Verfahren und stoffe zur bewertung einer immunantwort auf ein therapeutisches protein
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
AU2006235258A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
US8124351B2 (en) 2005-11-18 2012-02-28 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
AU2007269714A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries
EP2111224B1 (de) 2007-01-12 2016-07-13 University of Maryland, Baltimore Targeting des ncca-atp-kanals für organschutz nach einer ischämischen episode
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
WO2008137475A2 (en) 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries
EP2167528B1 (de) * 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modifizierte toxine
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
EP2245049B1 (de) 2008-01-10 2015-05-20 Research Development Foundation Impfstoffe und diagnostika für ehrlichiosen
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
AU2009313255B2 (en) 2008-11-07 2014-08-07 Research Development Foundation Compositions and methods for the inhibition of Cripto/GRP78 complex formation and signaling
EP2370092A1 (de) 2008-12-03 2011-10-05 Research Development Foundation Modulierung von olfml-3-vermittelter angiogenese
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2485762B1 (de) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4-assays
JP6174320B2 (ja) 2009-11-17 2017-08-02 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトヌクレオリンに対するヒトモノクローナル抗体
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
KR102489185B1 (ko) 2011-04-01 2023-01-17 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
US8663637B2 (en) 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US9567392B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
EP2841101B1 (de) 2012-04-26 2019-08-07 University Of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern zur neutralisierung der koagulaseaktivität bei einer staphylococcus-aureus-erkrankung
SG10201807059QA (en) 2012-05-10 2018-09-27 Massachusetts Inst Technology Agents for influenza neutralization
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2912064B1 (de) 2012-10-24 2019-04-24 Research Development Foundation Jam-c-antikörper und verfahren zur behandlung von krebs
WO2014127211A1 (en) 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
EP2970909A4 (de) 2013-03-15 2017-02-15 The University of Chicago Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
EP3524618B1 (de) 2013-03-15 2023-03-08 GLAdiator Biosciences, Inc. Gla-domänen als zielwirkstoffe
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
NZ631098A (en) 2013-03-15 2016-09-30 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
IL293871A (en) 2013-08-30 2022-08-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
EP3065775B1 (de) 2013-11-08 2020-09-30 The Board of Regents of the University of Texas System Vh4-antikörper gegen und neuron und astrozyt der grauen substanz
CN106103483A (zh) 2014-01-13 2016-11-09 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
JP6908381B2 (ja) 2014-01-29 2021-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
EP3104888A4 (de) 2014-02-11 2017-08-09 Massachusetts Institute Of Technology Neuartiger anti-dengue-vollspektrumsantikörper
CN106415269B (zh) 2014-05-08 2020-11-27 贵州美鑫达医疗科技有限公司 直接免疫组织化学测定
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
CA2959356C (en) 2014-08-27 2024-02-20 Memorial Sloan Kettering Cancer Center Novel antibodies that bind to b7h3
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
EP3256164B1 (de) 2015-02-09 2020-03-25 Memorial Sloan Kettering Cancer Center Multispezifische antikörpern mit affinität für menschliches a33-antigen und dota-metallkomplex
EP3262411B1 (de) 2015-02-25 2022-04-06 Vanderbilt University Antikörper-vermittelte neutralisierung von marburg-virus
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
AU2016354440B2 (en) 2015-11-09 2023-09-28 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2019507582A (ja) 2015-12-04 2019-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法用のｓｌｃ４５ａ２ペプチド
CN116672445A (zh) 2016-02-26 2023-09-01 德克萨斯大学体系董事会 连接蛋白(Cx)43半通道结合抗体及其用途
MX2018011939A (es) 2016-03-29 2019-05-20 Stcube Inc Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
JP7194595B2 (ja) 2016-07-01 2022-12-22 ザ ジェネラル ホスピタル コーポレイション グランザイムｂを指向するイメージングおよび治療
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
WO2018126183A2 (en) 2016-12-29 2018-07-05 The General Hospital Corporation Her3 peptides for imaging and radiotherapy
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
KR20200050975A (ko) 2017-09-05 2020-05-12 글래디에이터 바이오사이언시즈 인코포레이티드 엑소좀의 표적화 방법
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
EP4116327A1 (de) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
EP3735589A2 (de) 2018-01-05 2020-11-11 Vanderbilt University Antikörpervermittelte neutralisierung des chikungunya-virus
CN111971308A (zh) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-h4抗体及其使用方法
EP3768726A4 (de) 2018-03-23 2021-12-22 Board of Regents, The University of Texas System Antikörper mit doppelter spezifität für pd-l1 und pd-l2 und verwendungsverfahren dafür
US20210371518A1 (en) 2018-09-13 2021-12-02 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
EP4219550A1 (de) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoklonale antikörper gegen etld1 und verwendungen davon
JP2022513437A (ja) 2018-11-28 2022-02-08 オレゴン ヘルス アンド サイエンス ユニバーシティー 治療用第ｘｉｉ因子抗体
US20230132386A9 (en) 2019-02-13 2023-04-27 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
JP2022541538A (ja) 2019-07-19 2022-09-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア グリピカン２結合ドメインを含有するキメラ抗原受容体
CA3145278A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
AU2021220847A1 (en) 2020-02-11 2022-09-01 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
UY39135A (es) 2020-03-26 2021-10-29 Univ Vanderbilt ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4304660A1 (de) 2021-03-08 2024-01-17 ImmunoGen, Inc. Verfahren zur erhöhung der wirksamkeit von auf adam9 abzielenden immunkonjugaten zur behandlung von krebs
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
EP0155938A1 (de) * 1983-09-28 1985-10-02 Summa Medical Corporation Lektin-zusammensetzungen und verfahren zur diagnose von krebs
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0160446B1 (de) * 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Brusttumorassoziiertes Antigen und monoklonale Antikörper dazu
US4695538A (en) * 1984-06-01 1987-09-22 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Also Published As

Publication number Publication date
FI864037A0 (fi) 1986-10-06
DK478886D0 (da) 1986-10-07
JP2000000091A (ja) 2000-01-07
FI864037A (fi) 1987-04-08
NO863974D0 (no) 1986-10-06
EP0220858A3 (en) 1988-08-03
DK478886A (da) 1987-04-08
AU6356986A (en) 1987-04-09
NZ217829A (en) 1989-06-28
JP2968474B2 (ja) 1999-10-25
EP0220858B1 (de) 1993-02-10
US4938948A (en) 1990-07-03
IL80231A (en) 1991-08-16
EP0220858A2 (de) 1987-05-06
CA1338706C (en) 1996-11-12
ES2053440T3 (es) 1994-08-01
JPH08266273A (ja) 1996-10-15
JP2000000092A (ja) 2000-01-07
NO863974L (no) 1987-04-08
ATE85652T1 (de) 1993-02-15
DE3687736T2 (de) 1993-05-27

Similar Documents

Publication Publication Date Title
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
DK25084A (da) Human-human hybridoma mod neoplasmer
DE3483054D1 (de) Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
ES2061730T3 (es) Nuevos anticuerpos.
NL300040I2 (nl) Monoklonale antilichamen tegen borstkanker bij de mens, de bereiding en het gebruik ervan, en hybridoma's voor de produktie en bereiding ervan.
NZ222309A (en) Antibodies (including chimeric antibodies) to a human tumour antigen, polynucleotides encoding them, detection of the antigen by immunoassay and imaging methods and also cell killing methods
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
DE69522689D1 (de) Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper
EP0232871A3 (de) Menschlicher monoklonaler Antikörper, Hybridoma zu seiner Herstellung und seine Verwendung
ES8502547A1 (es) Un metodo para determinar la presencia de una neoplasia.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
EP0155172A3 (de) Monoklonale Antikörper gegen menschlichen Lungenkrebs
DE3784364T2 (de) Tumorassoziiertes antigen.
JPS6444856A (en) Anti-cancer antigen anti-serum
EP0278160A3 (de) Menschliche monoklonale Antikörper gegen Krebs, Hybridoma-Zellinien, die sie herstellen und ihre Anwendungen
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
JPS6439992A (en) Monoclonal antibody

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8339 Ceased/non-payment of the annual fee